Table 2. Schematic Representation of a Testing day in Six Treatment Conditions.
0900 hours | 0930 hours, T1 | 01000 hours, T2 | 01130 hours | 01130–01300 hours |
---|---|---|---|---|
Arrival | PLA | PLA | Vital-signs measurements and blood-sample collection | Memory tests |
Ketanserin | PLA | |||
Pindolol | PLA | |||
PLA | MDMA | |||
Ketanserin | MDMA | |||
Pindolol | MDMA |
During pre-treatment (T1) subjects received either placebo, ketanserin 50 mg or pindolol 20 mg. Treatment (T2) consisted of either MDMA 75 mg or placebo.